Shero Imaging Becomes First in Missouri to Offer IceCure’s Cryoablation for Breast Cancer
Event summary
- Shero Imaging in St. Louis becomes the first clinic in Missouri to offer IceCure’s ProSense® cryoablation for breast cancer.
- ProSense® received FDA marketing authorization for treating low-risk breast cancer in women aged 70+.
- Dr. Tish Singer, founder of Shero Imaging, will lead the cryoablation procedures.
- IceCure highlights the potential inclusion of ProSense® in proposed medical society treatment guidelines.
The big picture
IceCure’s ProSense® system is gaining traction beyond early adopters, with Shero Imaging’s adoption marking a strategic shift toward broader accessibility. The FDA’s marketing authorization and potential inclusion in medical guidelines position cryoablation as a viable alternative to surgery for low-risk breast cancer, particularly for older patients. This expansion into Missouri signals IceCure’s push to penetrate new geographic markets, potentially increasing its revenue and market share in the minimally invasive cancer treatment sector.
What we're watching
- Adoption Pace
- How quickly other clinics will adopt ProSense® following Shero Imaging’s lead in Missouri.
- Regulatory Influence
- Whether the proposed inclusion of ProSense® in medical society guidelines will accelerate market penetration.
- Competitive Response
- How competitors in the cryoablation space will react to IceCure’s expanding U.S. footprint.
Related topics